A phase II randomized trial of adjuvant chemotherapy with S-1 versus S-1 plus cisplatin for completely resected pathological stage II/IIIA non-small cell lung cancer. (October 2018)

• Record Type: Journal Article
• Authors: Okamoto, Tatsuro; Yano, Tokujiro; Shimokawa, Mototsugu; Takeo, Sadanori; Yamazaki, Koji; Sugio, Kenji; Takenoyama, Mitsuhiro; Nagashima, Akira; Tsukamoto, Shuichi; Hamatake, Motoharu; Yokoyama, Hideki; Ueda, Hitoshi; Motohiro, Akira; Tagawa, Tetsuzo; Shoji, Fumihiro; Kometani, Takuro; Saito, Genkichi; Fukuyama, Yasuro; Toyokawa, Gouji; Osoegawa, Atsushi; Emi, Yasunori; Maehara, Yoshihiko
• Is Part Of: Lung cancer. Volume 124(2018)
• Page Start: 255
• Page End: 259
• Publication Date: 2018-10
• Subjects: S-1 -- Cisplatin -- Adjuvant chemotherapy -- Non-small cell lung cancer -- Randomized phase II trial -- Multicenter study; Lungs -- Cancer -- Periodicals; Lung Neoplasms -- Abstracts; Lung Neoplasms -- Periodicals; Poumons -- Cancer -- Périodiques; Lungs -- Cancer; Periodicals; Electronic journals; Electronic journals; 616.99424
• DOI: 10.1016/j.lungcan.2018.08.015
• Languages: English
• ISSNs: 0169-5002

Abstract

Highlights: A randomized phase II trial for postoperative adjuvant chemo in stage II/III NSCLC. Long-term S-1 monotherapy versus S-1 with cisplatin followed by S-1 was investigated. Long-term adjuvant chemotherapy with S-1 was shown to be a promising treatment. Abstract: Objectives: Platinum-based combination chemotherapy is the standard postoperative adjuvant treatment for pathological stage II/III non-small cell lung cancer (NSCLC). Oral S-1 therapy has good efficacy and relatively low toxicity for the treatment of advanced NSCLC. We investigated whether long-term S-1 monotherapy is also useful as an adjuvant therapy after surgery in patients with NSCLC. Patients and methods: We conducted a phase II randomized open-label multi-institutional study in patients with pathological stage II/IIIA NSCLC (7 th TNM classification) who underwent complete resection from 2009 to 2013. The primary endpoint, the 2-year disease-free survival (DFS) rate, was evaluated using the Bayesian method. Eligible patients were randomly assigned to two arms: oral S-1 monotherapy (S-1 arm) and S-1 plus cisplatin combination therapy followed by S-1 (S-1 plus cisplatin arm) both for a total of 1 year. Results: A total of 70 and 71 patients were enrolled in S-1 arm and S-1 plus cisplatin arm, respectively. The 2-year DFS rates were 52% (95% confidence interval [CI], 0.40–0.63) and 61% (95% CI, 0.48–0.70) for S-1 arm and S-1 plus cisplatin arm, respectively. Both arms met the primary endpoint. Neither DFS nor OS was significantly different between the arms (log-rank test: P = 0.1695 and P = 0.8684, respectively). The main G3/4 adverse events were loss of appetite and anemia (S-1 vs. S-1 plus cisplatin: 4.3% vs. 11.6% and 0% vs. 5.8%, respectively). The treatment completion rate did not differ between the two arms (S-1 vs. S-1 plus cisplatin: 45.7%, 95% CI, 41.9–66.3% vs. 43.5% 95% CI, 44.0–68.4%). Conclusions: Long-term adjuvant chemotherapy with S-1 was a feasible and promising treatment for patients with completely resected NSCLC, regardless of cisplatin addition. S-1 monotherapy should be investigated further, based on its low toxicity and practical convenience.